The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management ...

PURPOSECannabis has been legalized across multiple states over the past decade; however, its use among cancer survivors ...

Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.

Purpose To provide evidence-based recommendations to practicing oncologists, surgeons, and radiation therapy clinicians to update the 2005 clinical practice guideline on the use of sentinel node ...

This matched retrospective cohort study examined the effect of an encounter with palliative care on health-care use at the end of life among 6,580 Medicare beneficiaries with advanced prostate, breast ...

This is a US Government work. There are no restrictions on its use. Views and interpretations presented in this manuscript are those of Drs Castle and Han alone and do not represent those of NCI, NIH, ...

Human Leukocyte Antigen Mismatching and the Role of Killer Cell Immunoglobulin-Like Receptor Mismatch in Hematopoietic Cell Transplantation for Hematologic Malignancies The following represents ...

In sharp contrast to many other cancer types, the incidence and mortality of endometrial cancer continue to grow. This unfortunate trend is, in no small part, a result of the worldwide obesity ...

The potential for guarantee-time bias (GTB), also known as immortal time bias, exists whenever an analysis that is timed from enrollment or random assignment, such as disease-free or overall survival, ...

Monoclonal antibodies directed against the immune checkpoint protein cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152)—ipilimumab and tremelimumab—have been investigated in metastatic melanoma and ...

Population-Based External Validation of a Competing-Risks Nomogram for Patients With Localized Renal Cell Carcinoma ...

Tumor necrosis factor α (TNF-α) may play a role in renal cell carcinoma (RCC). We performed two sequential phase II studies of infliximab, an anti–TNF-α monoclonal antibody, in patients with ...